Elevated expression of Nrf-2 and ABCG2 involved in multi-drug resistance of lung cancer SP cells

Drug Research

Volumn 65, Issue 10, 2014, Pages 526-531

  Yang, B ^a   Ma, Y F ^a   Liu, Y ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

cancer stem like cells; chemoresistance; Nrf2; self renewal; side population cells

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HOE 33342; MESSENGER RNA; OXALIPLATIN; PACLITAXEL; TRANSCRIPTION FACTOR NRF2; VERAPAMIL; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; NFE2L2 PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDE POPULATION CELL; SURVIVAL RATE; WESTERN BLOTTING; ADENOCARCINOMA; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NF-E2-RELATED FACTOR 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VERAPAMIL;

EID: 84941973678     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0034-1390458     Document Type: Article

References (29)

1. Schoenhals M., Kassambara A., De Vos J. et al. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun: 2009; 383 157 162
2. Chiou S. H., Wang M. L., Chou Y. T. et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res: 2010; 70 10433 10444
3. Parkin D. M., Bray F., Ferlay J. et al. Global cancer statistics, 2002. CA Cancer J Clin: 2005; 55 74 108
4. Jemal A., Siegel R., Ward E. et al. Cancer statistics, 2008. CA Cancer J Clin: 2008; 58 71 96
5. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin: 2012; 62 10 29
6. Salnikov A. V., Gladkich J., Moldenhauer G. et al. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Int J Cancer: 2010; 126 950 958
7. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene: 2010; 29 4741 4751
8. Ho M. M., Ng A. V., Lam S. et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res: 2007; 67 4827 4833
9. Das B., Tsuchida R., Malkin D. et al. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells: 2008; 26 1818 1830
10. Ho M. M., Ng A. V., Lam S. et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res: 2007; 67 4827 4833
11. Singh A., Wu H., Zhang P. et al. Expression of ABCG2 (BCRP), a Marker of Stem Cells, is regulated by Nrf2 in Cancer Cells That Confers Side Population and chemoresistance phenotype. Mol Cancer Ther: 2010; 9 2365 2376
12. He Q. Z., Luo X. Z., Wang K. et al. Isolation and characterization of cancer stem cells from high-grade serous ovarian carcinomas. Cell Physiol Biochem: 2014; 33 173 184
13. Shi Y., Fu X., Hua Y. et al. The Side Population in Human Lung Cancer Cell Line NCI-H460 Is Enriched in Stem-Like Cancer Cells. PLoS One: 2012; 7 e33358
14. Hirschmann-Jax C., Foster A. E., Wulf G. G. et al. A distinct side population of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad USA: 2004; 101 14228 14233
15. Kondo T., Setoguchi T., Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA: 2004; 101 781 786
16. Gil J., Stembalska A., Pesz K. A. et al. Cancer stem cells: the theory and perspectives in cancer therapy. App Genet: 2008; 49 193 199
17. Cho R. W., Clarke F. M. Recent advances in cancer stem cells. Current Opinion in Genetics & Development: 2008; 18 48 5
18. - cancer cells are similarly tumorigenic. Cancer Research: 2005; 65 6207 6219
19. Kensler T. W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol: 2007; 47 89 116
20. Bunting K. D. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells: 2002; 20 11 20
21. Kopper L., Hajdu M. Tumor stem cells. Pathol Oncol Res: 2004; 10 69 73
22. Eramo A., Lotti F., Sette G. et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ: 2008; 15 504 514
23. Itoh K., Chiba T., Takahashi S. et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun: 1997; 236 313 322
24. Ramos-Gomez M., Kwak M. K., Dolan P. M. et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA: 2001; 98 3410 3415
25. Kwak M. K., Kensler T. W., Casero R. A. Jr. Induction of phase 2 enzymes by serum oxidized polyamines through activation of Nrf2. effect of the polyamine metabolite acrolein. Biochem Biophys Res Commun: 2003; 305 662 670
26. Kobayashi A., Kang M. I., Okawa H. et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol: 2004; 24 7130 7139
27. Zhang D. D., Lo S. C., Cross J. V. et al. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol: 2004; 24 10941 10953
28. Singh A., Misra V., Thimmulappa R. K. et al. Dysfunctional KEAP1-NRF2 interaction in non-smallcell lung cancer. PLoS Med: 2006; 3 e420
29. Shibata T., Ohta T., Tong K. I. et al. Cancer related mutations in NRF2 impair its recognition byKeap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA: 2008; 105 13568 13573